YOLFTbeta
Bloomage Biotechnology Corp Ltd

Bloomage Biotechnology Corp Ltd

688363 · SHG · Basic Materials / Specialty Chemicals

33.16CNY-0.44 (-1.31%)

Price History

Full chart

Market Stats

Previous Close33.60
Open33.53
Day Range33.08 – 33.88
52-Week Range32.92 – 56.76
Volume1.79M
Market Cap16.77B
P/E (TTM)74.06
Forward P/E41.32
EPS0.47
Dividend Yield0.55%
Beta0.42
50-Day Avg36.36
200-Day Avg40.55

About

Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers beauty and care products under brand Hymagic-VCHA VC Hylauronic Acid; Biomeet-MarineDNA; Bioyouth-SPG Schizophyllan Gel; Hymagic-GluHA; Bloomsurfact EncapCare RP; Bloomsurfact Sodium Surfactin; Hybloom Minitrue; Bioyouth-EGT Pure Ultrapure Ergothioneine; miniHA HA-Oligo degraded by hyaluronidase; microHA Super Active Hyaluronic Acid; Hymagic-AcHA Sodium Acetylated Hyaluronate; Hymagic-4D 4D Hyaluronic Acid; Hybloom Zinc Hyaluronate; Hybloom Sodium Hyaluronate 1% Solution; Hybloom Sodium Hyaluronate; Hybloom Oligo Hyaluronic Acid; Hybloom Low Molecular Weight Sodium Hyaluronate; Hybloom Hydrolyzed Hyaluronic Acid; Hybloom High Molecular Weight Sodium Hyaluronate; Hyanutra-RH Hair Nourishing Shield; Hyafacto-PGA Super High Molecular Weight Sodium Polyglutamate; Hyafactor-PGA Sodium Polyglutamate; Hyafactor-NAG Acetyl Glucosamine; Hyacross TG100 Hyaluronic Acid Elastomer; Hyacolor Oil-dispersed Sodium Hyaluronate; Gabacare BL98T Aminobutyric Acid; cationHA-G and clear Substantive Sodium Hyaluronate; Bioyouth-Natto Natto Extract; Bioyouth-NANA N-Acetylneuraminic Acid; Bioyouth HT Silky Hyaluronic Acid; Bioyouth-EGT Pro Super Active Ergothione; Bioyouth-Brice Brown Rice Ferment Filtrate; Bioyouth-FCM Cordyceps Militaris Ferment Filtrate; Bioyouth-EGT Ergothioneine Complex; Bioyouth BLC Bluelight Care; Bioecto Ectoine; Biobloom Microecobeauty. It also provides pharma and aesthetics; nutrition and health products under the brand Hyatrue; Bloomecto; Bloomcolla; BloomseaN; BloomStem; MitoEGT L-Ergothioneine; UltraHA J Sodium Hyaluronate; MitoPQQ Pyrroloquinoline Quinone Disodium; UltraHA-CWS Sodium Hyaluronate; HAPLEX Plus Sodium Hyaluronate; Gabarelax Gamma Aminobutyric Acid; UltraHA-GI-001 Special sodium hyaluronate for gut health; and Biovivid Collagen Peptide name. Bloomage BioTechnology Corporation Limited was founded in 2000 and is based in Jinan, China.

Company Details

  • SectorBasic Materials
  • IndustrySpecialty Chemicals
  • CEOMs. Yan Zhao
  • Employees3.66K
  • HeadquartersNo. 678 Tianchen Street, Jinan, China, 250101, China
  • Websitehttps://www.bloomagebioactive.com

Leadership

  • Ms. Yan ZhaoChairman, GM & CEO · b. 1966
  • Mr. Hui WangDeputy GM, CFO & Director · b. 1983
  • Mr. Jiajun GuoDeputy GM & Director · b. 1975
  • Mr. Yizheng LiDeputy GM, Secretary of the Board & Director · b. 1984
  • Mr. Mao Gong XiangDeputy General Manager · b. 1984
  • Tao TianAccounting Supervisor
  • Ms. Yanli ShiChief Technology Officer of Raw Material R&D · b. 1971

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue274.97M375.18M481.30M650.87M733.12M818.05M1.26B1.89B2.63B4.95B6.36B6.08B5.37B4.20B
Growth (%)-+36.45%+28.29%+35.23%+12.64%+11.58%+54.41%+49.28%+39.63%+87.93%+28.53%-4.45%-11.61%-21.82%
Cost of Revenue84.32M75.32M105.90M163.63M170.62M206.47M258.67M389.74M510.98M1.12B1.48B1.66B1.48B1.25B
Gross Profit190.65M299.86M375.40M487.24M562.50M611.58M1.00B1.50B2.12B3.83B4.88B4.42B3.89B2.95B
Gross Margin69.34%79.92%78.00%74.86%76.73%74.76%79.52%79.33%80.59%77.40%76.69%72.69%72.40%70.33%
Operating Expense73.41M164.12M167.66M232.61M242.04M327.28M480.03M796.25M1.36B2.92B3.74B3.71B3.67B2.49B
Operating Income117.24M135.74M207.74M254.63M320.46M284.30M524.45M699.58M757.05M905.55M1.14B708.39M215.94M459.21M
Operating Margin42.64%36.18%43.16%39.12%43.71%34.75%41.52%37.10%28.76%18.30%17.87%11.66%4.02%10.94%
EBITDA127.62M144.29M215.72M287.19M337.89M321.08M528.94M729.43M740.23M866.92M1.12B775.49M465.45M698.04M
EBITDA Margin46.41%38.46%44.82%44.12%46.09%39.25%41.88%38.69%28.12%17.52%17.68%12.76%8.67%16.62%
Net Income89.27M94.40M162.07M190.39M269.43M222.27M423.86M585.61M645.84M782.33M970.92M592.56M174.27M292.06M
Net Income Margin32.47%25.16%33.67%29.25%36.75%27.17%33.56%31.06%24.53%15.81%15.27%9.75%3.24%6.96%
R&D9.71M15.15M15.65M29.80M23.96M25.72M52.87M93.89M141.16M284.34M388.19M446.35M466.25M472.14M
R&D as % of Total Revenue3.53%4.04%3.25%4.58%3.27%3.14%4.19%4.98%5.36%5.75%6.10%7.35%8.68%11.24%
Interest Expense-9.98M9.62M16.73M216.23K3.08M765.39K2.07M517.07K11.88M15.06M11.56M10.13M6.42M
Interest Expense % of Total Revenue-2.66%2.00%2.57%0.03%0.38%0.06%0.11%0.02%0.24%0.24%0.19%0.19%0.15%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets474.26M768.31M965.44M2.20B1.68B1.88B2.07B4.97B5.72B7.50B8.68B8.47B8.66B8.69B
Total Liabilities97.29M203.96M212.94M1.01B423.53M245.35M353.56M422.11M622.68M1.80B2.00B1.49B1.82B1.58B
Total Equity376.89M564.29M752.46M1.19B1.26B1.64B1.72B4.55B5.02B5.70B6.63B6.94B6.81B7.09B
Cash120.81M266.43M267.84M906.05M557.56M331.87M853.92M2.20B1.39B1.81B1.61B1.17B719.27M994.98M
Total Debt54.75M90.64M53.63M851.28M220.00M-40.00M-89.35M300.01M389.79M208.10M268.01M-
Net Debt-66.32M-175.79M-214.21M-54.77M-337.56M-331.87M-813.92M-2.20B-1.37B-1.51B-1.22B-960.62M-451.26M-

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow83.62M155.33M137.47M145.67M241.68M343.42M442.30M364.89M705.12M1.28B635.19M699.65M564.51M627.45M
Investing Cash Flow-140.26M-167.64M-71.42M-445.03M-17.66M-328.50M-34.52M-1.25B-1.33B-989.86M-836.22M-620.66M-461.37M-
Financing Cash Flow-11.02M62.81M-47.67M991.25M208.46M-230.76M85.22M2.22B-159.94M-71.36M-170.16M-533.57M-310.52M-
Capital Expenditure46.53M114.13M118.45M266.97M19.91M46.00M168.42M450.23M762.77M784.21M696.41M1.03B721.39M325.68M
Free Cash Flow37.09M41.20M19.02M-121.31M221.76M297.42M273.88M-85.34M-57.65M491.85M-61.22M-330.68M-156.88M301.77M
Dividends Paid2.79M5.04M4.96M6.58M11.54M15.76M1.01B177.60M177.60M196.80M235.73M305.48M185.93M56.08M
FCF to OCF44.36%26.52%13.84%-83.28%91.76%86.61%61.92%-23.39%-8.18%38.54%-9.64%-47.26%-27.79%48.10%
Dividend Paid to FCF7.52%12.24%26.07%-5.42%5.20%5.30%368.70%-208.12%-308.04%40.01%-385.04%-92.38%-118.51%18.58%

Earnings

Report DateApr 28, 2020Aug 25, 2020Oct 29, 2020Apr 29, 2021Aug 31, 2021Oct 26, 2021Mar 10, 2022Apr 25, 2022Jul 20, 2022Oct 28, 2022Feb 27, 2023Apr 28, 2023Aug 29, 2023Oct 30, 2023Feb 28, 2024Apr 29, 2024Aug 23, 2024Oct 30, 2024Feb 27, 2025Apr 25, 2025Aug 26, 2025Sep 30, 2025Feb 27, 2026Mar 31, 2026Aug 27, 2026
EPS Estimate----0.530.301.231.230.531.250.240.490.63-0.040.890.890.640.280.280.630.520.260.230.270.24
EPS Actual0.230.330.360.320.430.290.450.420.470.390.610.420.460.190.150.160.200.04-0.410.210.250.070.090.140.18
Surprise-----18.87%-3.33%-63.41%-65.85%-11.32%-68.80%154.17%-14.29%-26.98%575.00%-83.15%-82.02%-68.75%-85.71%-246.43%-66.67%-51.92%-72.95%-60.87%-48.24%-25.00%
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-Pre-market

Key Statistics & Ratios

Market Cap16.77B
Enterprise Value16.22B
Trailing P/E74.06
Forward P/E41.32
Price / Sales4.54
Price / Book2.38
EPS0.47
Book Value14.82
Revenue (TTM)3.69B
Gross Profit (TTM)2.46B
EBITDA422.22M
Profit Margin6.06%
Operating Margin2.97%
Return on Equity3.15%
Return on Assets0.73%
Shares Outstanding481.68M
Shares Float193.31M
Beta0.42
Dividend Yield0.55%
Dividend Rate0.19
Payout Ratio23.40%

Dividends

20231×
0.61Jun 21, 2023
20221×
0.49May 16, 2022
20211×
0.41Jul 16, 2021
20201×
0.37Jul 17, 2020